Table 1.
The demographic characteristics of 109 advanced GIST patients under Sunitinib therapy.
| Variables | No. | Percentage (%) or Mean ± SD |
|---|---|---|
| Basic data | ||
| Gender | ||
| Male/Female | 63/46 | 57.8/42.2 |
| Age (years) | 60.9 ± 13.6 | |
| ECOG when start | ||
| 0/1/2 | 24/47/22 | 22.0/43.1/20.2 |
| 3 | 16 | 14.7 |
| Body composition | ||
| Weight (kg) | 61.0 ± 12.6 | |
| Height (cm) | 160.0 ± 8.5 | |
| BMI (kg/m2) | 23.7 ± 4.0 | |
| BMI grading (kg/m2) | ||
| <18.5 | 8 | 7.3 |
| 18.5–27 | 83 | 76.2 |
| >27 | 18 | 16.5 |
| Albumin > 3.5 (g/dL) | ||
| Yes | 65 | 40.4 |
| No | 44 | 59.6 |
| Tumor characteristics | ||
| Tumor size (cm) | 10.4 ± 6.0 | |
| Location | ||
| Stomach | 39 | 35.8 |
| Small bowel | 53 | 48.7 |
| Colorectal | 8 | 7.3 |
| Peritoneum | 1 | 0.9 |
| Other | 8 | 7.3 |
| Liver Metastasis | ||
| Yes/No | 70/39 | 64.2/35.8 |
| Genetic mutation when using sunitinib (N = 109) | ||
| Exon 9 | 15 | 13.8 |
| Exon 9 and 17 | 2 | 1.8 |
| Exon11 | 36 | 33.0 |
| Exon 11 and 13 | 14 | 12.8 |
| Exon 11 and 17 | 8 | 7.3 |
| Wild type | 5 | 4.6 |
| Unknown | 29 | 26.6 |
| Sunitinib dosage | ||
| Dosage divided b | ||
| Yes/No | 70/39 | 64.2/35.8 |
| Initial dosage (mg) | ||
| 25 | 17 | 15.6 |
| 37.5 | 79 | 72.5 |
| 50 | 13 | 11.9 |
| Directly shift to sunitinib c | ||
| Yes/No | 49/60 | 45.0/55.0 |
Note: Abbreviation: GIST: Gastrointestinal Stromal Tumor; SD: Standard Deviation; ECOG, Eastern Clinical Oncology Group performance status; BMI, body mass index. b Standard dosage of sunitinib (50 mg QD) was given for 4 weeks, followed by a two-week drug-free period. In the study, we divided the dosage into 12.5 mg QID/25 mg BID to reduce the toxicity. c. When the GIST patients experienced disease progression during imatinib use, the patients would receive imatinib escalation or a direct shift to sunitinib.